Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PNK-007 + aldesleukin
- Development stage
- Unknown
- Lead developer
- Celularity
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
PNK-007 + aldesleukin is an investigational combination immunotherapy consisting of allogeneic, off-the-shelf natural killer (NK) cells and a recombinant cytokine. **PNK-007** (also known as **CYNK-001**) is a cell therapy product enriched for CD56+/CD3- NK cells that are expanded from human placental CD34+ hematopoietic stem cells. These NK cells exhibit direct cytotoxicity against various hematologic malignancies, including multiple myeloma and acute myeloid leukemia. **Aldesleukin** (recombinant human interleukin-2) is co-administered subcutaneously to facilitate the expansion, persistence, and activation of the infused NK cells in vivo. The combination is primarily evaluated in the post-autologous stem cell transplant (ASCT) setting or following lymphodepleting chemotherapy to enhance immune reconstitution and target residual cancer cells through NK cell-mediated cytotoxicity.
- Other names
- PNK-007 + recombinant human interleukin-2PNK-007 + rhIL-2placental-derived natural killer cells + IL-2
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on PNK-007 + aldesleukin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PNK-007 + aldesleukin.